Vaccines Overview
I've collected the below data mostly for my own amusemment, because it is difficult to keep track of all the data. It is based on data I have gathered from what I consider reputable sources. However they are not necessarily from peer reviewed scientific papers, but often from a general news media. Also note that I am not a scientist in this field, so use with care.

			Strains
			Novel	British (alfa) (B.1.1.7)	South African (beta) (B.1.351)	Brazilian (gamma) (B.1.1.28.1 / P.1)	Indian (delta) (B.1.617.x)
		Contagiousness	1.0	1.3-1.7	?	claimed up to 3.0	?
		Mutations *)	-	N501Y	E484K	N501Y, E484K	L452R / E484Q
		Additional information		info	info	info	info
Vaccine	Origin	Type	Efficacy					Approved by EU	Price per Dose a)
Pfizer-BioNTech (Comirnaty)	US/Germany	mRNA	95% 4)	93.7% (50% @3w)	~31% 3)	Likely ~31%	88% 1) (36% @3w)	Yes (2020-12-21)	USD 10-20 EUR 12 (EU)
Moderna	US	mRNA	94%	?	?	?	?	Yes (2021-01-06)	USD 10-50 USD 18 (EU)
Oxford/AstraZeneca	UK/Sweden	Viral vector, adenovirus ChAdOx1	76%	66% (50% @3w)	10% 2)	Likely ~10%	67% (30% @3w)	Yes (2021-01-29)	USD 3-4 EUR 1.78 (EU)
Johnson & Johnson	US	Viral vector; adenovirus 26	66%	?	57% 1)	Likely ~57%	?	Yes (2021-03-11)	USD 10 USD 8.50 (EU)
Novavax	US	Protein based	96%	86%	60%	Likely ~60%	?	Under rolling review	USD 16
CureVac	Germany	mRNA	~50%	?	?	?	?	On pause due to poor performance	EUR 10 (EU)
Sputnik V	Russia	Viral vector; adenovirus 5 and 26	~90%	?	?	99% (85% @2w)	?	Under rolling review	USD 10
Sinovac (CoronaVac)	China	Inactivated SARS‑Cov‑2	~50%	?	?	?	?	Under rolling review	USD 30-60
Vidprevtyn (Sanofi/GSK)	France/UK	Protein based	~95%	?	?	?	?	Under rolling review	EUR 7,56 (EU)
Sinopharm	China	Inactivated SARS‑Cov‑2	Claimed ~80%	?	?	?	?	No	USD 19-36
Covaxin	India	Inactivated SARS‑Cov‑2	?	?	?	?	?	No	USD ~4

If two efficacy values are shown the first is two weeks after both shots, and the one in paranthesis is a number of weeks after the first shot. For instance "@3w" means 3 weeks after the first shot.

For comparison flu vaccines are typically 29% to 48% effective.

Note *: N501Y is linked to higher contagiousness; E484K is likely evading antibodies from previous strains (and current vaccines). Source and source.

Note a: (EU) is the price for the EU region. Other price ranges are what other regions are paying.

Note 1: At least for the Johnson & Johnson trial in South Africa, though the vaccine was less efficient at preventing all sympthoms, severe cases requiring hospitalizations was very low. So it still offers strong protection, however it likely does not prevent contamination from person to person. The same seems to be true for the Pfizer vaccine against the Indian version, as an Israeli study seems to suggest that it is only 64% effective against mild to moderate cases, but 93% effective against severe cases.

Note 2: The comments under note 1 likely also apply to the Oxford/AstraZeneca vaccine, although trials have indicated only 10-22% effectiveness against mild-to-moderate cases. Source (Reuters) and source (The Guardian).

Note 3: The comments under note 1 likely also apply source (Reuters). Also note that there are reports suggesting that the Pfizer-BioNTech vaccine has high efficacy against the South African strain, while other reports suggest the exact opposite.

Note 4: This study from Israel shows how remarkably efficient the Pfizer-BioNTech vaccine is against A. infections, B. Symptoms, C. Hospitalization, D. Severe cases, and E. Death: New England Journal of Medicine, especially figure 2.

Additional Sources
https://www.gov.uk/government/news/vaccines-highly-effective-against-b-1-617-2-variant-after-2-doses

Additional Information
It seems overweight is associated with severity of covid-19 and the need for hospital treatment:

For obese people (BMI > 30) there is 200 to 240% increased odds for developing severe Covid-19. They are 2-5 times more likely to need of intensive care, 3-6 times more likely to need respirator, 3-6 times more likely to die.

For overweight people (BMI of 25 to 30) there is 67 to 84% increased odds for developing severe Covid-19.

Source (World Obesity Federation)

Source (British Journal of Sports Medicine)

Other Slightly Related Links
This site has some maps that shows the travel recommendations as seen from the Danish governments viewpoint.

Danish SSI's description of variants.